Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis.

Published in: British journal of clinical pharmacology (2023)

Regdanvimab was not effective in reducing mortality and hospital admission rate in patients with mild to moderate COVID-19, but it was effective in improving other efficacy outcomes. Further research is needed to confirm these findings.

Keyphrases

coronavirus disease
sars cov
emergency department
healthcare
cardiovascular events
respiratory syndrome coronavirus
cardiovascular disease
adipose tissue
acute care
adverse drug
loop mediated isothermal amplification
coronary artery disease
sensitive detection